Issue of Equity
Updated : 15:00
Physiomics plc
("Physiomics") or ("the Company")
Issue of Equity
Physiomics plc announces today that following the receipt of notice of exercise of employee options, 1,768,815 Ordinary Shares of 0.4p each in the Company (the "Options Shares") have now been issued to the following employees at the following exercise prices:
Grantee | Number of shares issued | Exercise price per option |
Dr J Millen, CEO | 484,641 | 2.5p |
Dr C Chassagnole, COO | 645,231 | 3.5p |
Dr C Chassagnole, COO | 219,880 | 2.5p |
Other staff | 96,448 | 2.5p |
Other staff | 322,615 | 3.5p |
Application has been made to admit the Option Shares to trading on AIM, and dealings in the Option Shares are expected to commence on 12th December 2017.
Following the issue of the Option Shares, the total holdings of each Director of the Company will be as follows:
Dr Paul Harper 525,707
Dr Jim Millen 684,641
Dr Christophe Chassagnole 1,017,008
Following the issue of the Option Shares, the total number of shares now in issue is 58,785,394 Ordinary Shares with voting rights attached (one vote per Share). There are no Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the Disclosure and Transparency Rules.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | James Millen | ||||
2 | Reason for the notification | |||||
a) | Position/status | Director, CEO | ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Physiomics plc | ||||
b) | LEI | 213800A71DSZ6ABMTQ91 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary share
GB00BDR6W943 | ||||
b) | Nature of the transaction | Share Incentive Plan purchase | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
484,641 At 2.5p per share | ||||
e) | Date of the transaction | 6-12-2017 | ||||
f) | Place of the transaction | XLON, AIM |
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
a) | Name | Christophe Chassagnole | ||||||
2 | Reason for the notification | |||||||
a) | Position/status | Director, COO | ||||||
b) | Initial notification/ Amendment | Initial notification | ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | Physiomics plc | ||||||
b) | LEI | 213800A71DSZ6ABMTQ91 | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary share
GB00BDR6W943 | ||||||
b) | Nature of the transaction | Share Incentive Plan purchase | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information - Aggregated volume - Price |
865,111 At 2.5p and 3.5p as shown in table above | ||||||
e) | Date of the transaction | 6-12-2017 | ||||||
f) | Place of the transaction | XLON, AIM |
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
Katy Mitchell, James Sinclair-Ford
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.
This information is provided by RNS